Xiaoyan Yang
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy.
Journal: Redox biology
Published: January 10, 2025
Corrigendum to "PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2" [Journal of Molecular and Cellular Cardiology. 172(2022) 63-77].
Journal: Journal of molecular and cellular cardiology
Published: November 23, 2024
β2-Adrenergic Receptor Agonist Clenbuterol Protects Against Acute Ischemia/Reperfusion-Induced Arrhythmia by Regulation of Akt/eNOS/NO/Cx43 Signaling Pathway.
Journal: Pharmacology research & perspectives
Published: September 16, 2024
Establishment of a Necroptosis-Related Prognostic Signature to Reveal Immune Infiltration and Predict Drug Sensitivity in Hepatocellular Carcinoma.
Journal: Frontiers in genetics
Published: March 21, 2022
VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis.
Journal: Metabolism: clinical and experimental
Published: February 24, 2022
Long-Acting β2 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis.
Journal: Frontiers in pharmacology
Published: January 30, 2022
PDE4D binds and interacts with YAP to cooperatively promote HCC progression.
Journal: Cancer letters
Published: January 24, 2022
Deacetylation of Caveolin-1 by Sirt6 induces autophagy and retards high glucose-stimulated LDL transcytosis and atherosclerosis formation.
Journal: Metabolism: clinical and experimental
Published: November 24, 2021
PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2.
Journal: Journal of molecular and cellular cardiology
Published: November 09, 2021
Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.
Journal: Diabetes
Published: October 07, 2021
Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Journal: Pharmacological research
Published: August 07, 2021
Leptin gene-targeted editing in ob/ob mouse adipose tissue based on the CRISPR/Cas9 system.
Journal: Journal of genetics and genomics = Yi chuan xue bao
Published: October 27, 2020
Last Updated: 09/26/2026